Advertisement

Picture Campus Berlin-Buch GmbH CBB Location of Future Innovation 650x100px
Employment/Membership › Details

Ubiquigent–Amijee H: management, 202211– Head of Business Development before Cellesce + RxCelerate + Total Scientific + Senexis

 

Period Period 2022-11-07
Organisations Organisation Ubiquigent Ltd.
  Organisation 2 Cellesce Ltd.
Products Product drug discovery services
  Product 2 DUB inhibitor
Person Person Amijee, Hozefa (Ubiquigent 202211– Head of Business Development before Cellesce + RxCelerate + Total Scientific)
     

Ubiquigent Ltd.. (11/7/22). "Press Release: Ubiquigent Appoints Dr Hozefa Amijee as Head of Business Development". Dundee.

Appointment will strengthen outsourcing of DUB-focused drug discovery services and capabilities to clients and partners


Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced the appointment of Dr Hozefa Amijee as Head of Business Development (BD). As Ubiquigent enters the next phase of its development, the appointment will further improve access to the Company’s specialist CRO services and strengthen commercial partnerships, to meet the growing interest in the therapeutic potential of the DUB family of enzymes.

Hozefa joins Ubiquigent from Cellesce Ltd where, as Head of BD, he focused on growing partnerships and strategic alliances with top biotech and pharma companies, bringing the use of better patient-centric organoid models to drug discovery and development. He has over 20 years’ scientific and commercial experience in the life sciences industry, ranging from small biotech R&D to bespoke CRO and CDMO offerings, with Cambridge-based scientific roles at RxCelerate, Total Scientific and Senexis. Hozefa completed his PhD in Biochemistry at the University of Manchester, exploring amyloid aggregation inhibitors as a therapeutic strategy for Alzheimer’s disease treatment.

Dr Hozefa Amijee, Head of BD, Ubiquigent, said: “Ubiquigent is uniquely positioned to drive forward the discovery of novel DUB modulators, key to the development of powerful new medicines, and I am thrilled to be joining the Company at such a key stage in its commercial growth. I look forward to working closely with the team to support new and existing clients through the drug discovery process.”

Jason Mundin, Chief Executive Officer, Ubiquigent commented: “We are delighted to welcome Hozefa to the Ubiquigent team. Hozefa brings an impressive combination of technical know-how and commercial expertise, and we are confident that he will be invaluable in leading our continued development in the growing DUB field.”

To learn more about Ubiquigent’s DUB-focused drug discovery platform and services, contact services@ubiquigent.com or visit www.ubiquigent.com.


ENDS


Notes to Editors


Dr Hozefa Amijee,
Head of Business Development, Ubiquigent

Jason Mundin,
Chief Executive Officer, Ubiquigent


Media Contact

Sarah Jeffery
Zyme Communications
E-mail: sarah.jeffery@zymecommunications.com
Phone: +44 (0) 7771 730 919


Ubiquigent Ltd

Jason Mundin
CEO
E-mail: jason.mundin@ubiquigent.com
Phone: +44 (0) 1382 472654


About Ubiquigent www.ubiquigent.com

Ubiquigent enables the discovery and development of novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need.

Founded 13 years ago, the Company has an unrivalled track record and unique range of specialist services focused on the exploitation of the DUB enzymes and ubiquitin-proteasome system (UPS).

Ubiquigent is the partner chosen by many leading industry and academic organisations for their drug discovery programmes spanning the development of DUB inhibitors and modulators in the fields of protein degradation, stabilisation and homeostasis.

Ubiquigent has an internal pipeline of drug discovery programmes and is developing a strong IP portfolio encompassing DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs) and DUB-Targeting Chimeras (DUBTACs) for subsequent commercialisation via partnerships and out-licensing agreements. 

The Company benefits from high calibre backing, including from IP Group PLC, Scottish Enterprise, the UK Medical Research Council (MRC) and the University of Dundee. Based in a state-of-the-art facility located near the University of Dundee, it sits at the centre of a range of highly relevant additional scientific expertise and capabilities.

Follow Ubiquigent on LinkedIn (@Ubiquigent Ltd) and Twitter (@ubiquigent).

   
Record changed: 2022-11-08

Advertisement

Picture [iito] No Tracking 650x100px

More documents for Ubiquigent Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Campus Berlin-Buch GmbH CBB Location of Future Innovation 650x300px




» top